Diabetes area patent participation analysis – part II: years 2011-2016
| Autor: | Jamie E. Moscovitz, Markus Boehm, Matthew E. Crawford, Philip A. Carpino |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Blood Glucose
0301 basic medicine Pediatrics medicine.medical_specialty Diabetes Complications Patents as Topic 03 medical and health sciences 0302 clinical medicine Insulin-Secreting Cells Internal medicine Diabetes mellitus mental disorders Drug Discovery Diabetes Mellitus medicine Humans Hypoglycemic Agents Insulin Metabolic disease Pharmacology Plasma glucose biology business.industry Type 2 Diabetes Mellitus General Medicine medicine.disease Obesity Insulin receptor 030104 developmental biology GPR119 Drug Design 030220 oncology & carcinogenesis Disease Progression biology.protein business |
| Zdroj: | Expert Opinion on Therapeutic Patents. 28:111-122 |
| ISSN: | 1744-7674 1354-3776 |
| DOI: | 10.1080/13543776.2018.1406477 |
| Popis: | Diabetes is a metabolic disease characterized by elevated levels of plasma glucose. When untreated, diabetes increases the risk of developing co-morbidities such as cardiovascular disease. Several drugs, often used as part of combination therapies, have been approved to treat the disease, but these drugs will eventually fail to effectively control blood glucose levels, at which point insulin replacement therapy is required. A medical need exists for new antidiabetic drugs that exhibit good efficacy with improved safety/toleration profiles and can be added on top of existing therapies, or that can provide additional benefits beyond glucose lowering such as pancreatic beta (β)-cell protection.This review analyzes drug targets and applicants of patents that published between 2011-2016 claiming novel small or large molecules for the treatment of diabetes, and compares the results to the 2008-2010 time period.A majority of patent activity around the discovery of new antidiabetic drugs in 2011-2016 was directed against 15 targets, most of which were also the focus of drug discovery efforts in the 2008-2010 time period. The top targets by total patent counts were DPP4, GLP1R, INSR, GPR119, and SGLT2 (SLC5A2). With the exception of GPR119, these are the pharmacological targets of some of the best-selling antidiabetic drugs currently on the market. The top targets of patent families with the largest size counts, a metric useful in assessing patent value and applicant interest, were AMPK, CALCR, DPP4, and GLP1R. The patent analysis identified several emerging targets with greater patent activity in 2011-2016 compared to 2008-2010, including FFAR1, FFAR4, and FGFR1. Most of the patent activity in 2011-2016 was directed at established and precedented diabetes targets, the modulation of which may lead to improvements in glucose control and a delay in the progression of the disease. Few targets were identified that promote pancreatic β-cell regeneration and β-cell health, areas where future opportunities may exist for developing transformative drug therapies that may potentially lead to cures for diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|